UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.LBA360-LBA360

2024

Volltextzugriff (PDF)

Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.131-131

2023

Volltextzugriff (PDF)

First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.411-411

2023

Volltextzugriff (PDF)

Trayectoria histórica de la formación inicial de profesores de inglés 1960-2019: el discurso de los académicos

Logos (La Serena, Chile), 2022-07, Vol.32 (1), p.3-19

2022

Volltextzugriff (PDF)

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.4-4

2019

Volltextzugriff (PDF)

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4002-4002

2021

Volltextzugriff (PDF)

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4013-4013

2021

Volltextzugriff (PDF)

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2018-11, Vol.132 (Supplement 1), p.155-155

2018

Volltextzugriff (PDF)

Mariano Ruperthuz Honorato, Freud y los chilenos : un viaje transnacional (1910-1949): Santiago, Editorial Pólvora, 2015, 291 p

Nuevo mundo, mundos nuevos, 2017-12

Godoy Yáñez, Eduardo

2017

Volltextzugriff (PDF)

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Journal of clinical oncology, 2023-12, Vol.41 (36), p.5505-5511

2023

Volltextzugriff (PDF)

Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.4045-4045

2024

Volltextzugriff (PDF)

Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non–Small-Cell Lung Cancer from Chile, Brazil, and Peru

The Journal of molecular diagnostics : JMD, 2021-09, Vol.23 (9), p.1127-1137

2021

Volltextzugriff (PDF)

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4014-4014

2023

Volltextzugriff (PDF)

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5500-5500

2023

Volltextzugriff (PDF)

Design and Development of a Competitive Low-Cost Robot Arm with Four Degrees of Freedom

Modern mechanical engineering, 2011-11, Vol.1 (2), p.47-55

2011

Volltextzugriff (PDF)

Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin

Journal of clinical oncology, 2016-06, Vol.34 (18_suppl), p.LBA503-LBA503

2016

Volltextzugriff (PDF)

Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.LBA503-LBA503

2016

Volltextzugriff (PDF)

Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5506-5506

2022

Volltextzugriff (PDF)

FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5619-TPS5619

2022

Volltextzugriff (PDF)

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Blood, 2021-11, Vol.138 (Supplement 1), p.3538-3538

2021

Volltextzugriff (PDF)

Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT001-CT001

2021

Volltextzugriff (PDF)

Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.GS01-05-GS01-05

2024

Volltextzugriff (PDF)

La vestimenta de los esclavos en el Buenos Aires posrevolucionario: un análisis a través de los avisos de fugas y extravíos publicados en La Gaceta Mercantil de Buenos Aires (1823-1831)

Anuario del Instituto de Historia Argentina, 2013-12 (13)

Andrés Eduardo Yañez

2013

Volltextzugriff (PDF)

Cuál es el Rol de la Cirugía en el Tratamiento de un Paciente con Cáncer de la Vesícula Biliar Estadio IIIb?

International journal of morphology, 2015-06, Vol.33 (2), p.653-659

2015

Volltextzugriff (PDF)

51 – 75 von 543

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(419)
Mit Volltextzugriff
(418)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(240)
Life Sciences & Biomedicine
(164)
Humans
(76)
Female
(53)
Physical Sciences
(48)
Technology
(47)
Male
(41)
Middle Aged
(34)
Engineering
(33)
Aged
(32)
Adult
(31)
Computer Science
(26)
Chemistry
(21)
Environmental Sciences & Ecology
(20)
Engineering, Electrical & Electronic
(19)
Oncology
(19)
Medicine, General & Internal
(18)
Patients
(18)
Environmental Sciences
(17)
Computer Science, Theory & Methods
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(21)

Menü

Weitere Dienste

Einstellungen

Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T

Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC)

First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results

Trayectoria histórica de la formación inicial de profesores de inglés 1960-2019: el discurso de los académicos

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1)

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study

Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Mariano Ruperthuz Honorato, Freud y los chilenos : un viaje transnacional (1910-1949): Santiago, Editorial Pólvora, 2015, 291 p

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study

Concordance Analysis of ALK Gene Fusion Detection Methods in Patients with Non–Small-Cell Lung Cancer from Chile, Brazil, and Peru

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer

Design and Development of a Competitive Low-Cost Robot Arm with Four Degrees of Freedom

Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin

Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin

Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826

FLORA-5/GOG3035: Frontline chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] versus chemotherapy (paclitaxel-carboplatin-placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double-blind, placebo-controlled, global, multinational study

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Copanlisib Plus Rituximab with Placebo Plus Rituximab

Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)

Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial

La vestimenta de los esclavos en el Buenos Aires posrevolucionario: un análisis a través de los avisos de fugas y extravíos publicados en La Gaceta Mercantil de Buenos Aires (1823-1831)

Cuál es el Rol de la Cirugía en el Tratamiento de un Paciente con Cáncer de la Vesícula Biliar Estadio IIIb?

Suchergebnisse filtern